ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,136.87
0.20%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Phio Pharmaceuticals Corporation (PHIO)

  7. Phio Pharmaceuticals Corporation (PHIO) News

Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHIO
DateTimeSourceHeadlineSymbolCompany
28/05/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202422:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
20/05/202421:59Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202421:45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202414:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202414:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202414:00GlobeNewswire Inc.Phio Pharmaceuticals Secures New InvestorNASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
17/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/05/202413:00GlobeNewswire Inc.Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
15/05/202418:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202422:25GlobeNewswire Inc.Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202422:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHIOPhio Pharmaceuticals Corporation
09/05/202422:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202422:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202422:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PHIOPhio Pharmaceuticals Corporation
08/05/202422:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PHIOPhio Pharmaceuticals Corporation
30/04/202412:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)NASDAQ:PHIOPhio Pharmaceuticals Corporation
22/04/202418:10GlobeNewswire Inc.Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsNASDAQ:PHIOPhio Pharmaceuticals Corporation
16/04/202412:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)NASDAQ:PHIOPhio Pharmaceuticals Corporation
11/04/202412:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)NASDAQ:PHIOPhio Pharmaceuticals Corporation
03/04/202412:30GlobeNewswire Inc.National Spotlight Features Phio’s Innovative RNAi Technology PlatformNASDAQ:PHIOPhio Pharmaceuticals Corporation
02/04/202412:30GlobeNewswire Inc.Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateNASDAQ:PHIOPhio Pharmaceuticals Corporation
21/03/202411:30GlobeNewswire Inc.Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
13/03/202418:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202415:30GlobeNewswire Inc.Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/03/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
21/02/202400:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHIOPhio Pharmaceuticals Corporation
06/02/202415:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PHIOPhio Pharmaceuticals Corporation
31/01/202413:00GlobeNewswire Inc.Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesNASDAQ:PHIOPhio Pharmaceuticals Corporation
 Showing the most relevant articles for your search:NASDAQ:PHIO

Your Recent History

BIT
P1I618
BNP Paribas Issuance
EU
3LTS
Graniteshares Financial ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved